Home › Funds › Caligan Partners LP › XENE

Caligan Partners LP position in XENE

XENON PHARMACEUTICALS INC · Health Care

Caligan Partners LP reported holding 889,944 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$53.7M, representing 3.14% of its reported portfolio and ranking #7 among its reported holdings. Caligan Partners LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)889.94K sh
Reported value held$53.72M
Portfolio Weight3.14%
First reportedQ3 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Caligan Partners LP's XENE position evolved

Caligan Partners LP first disclosed a stake in XENE in Q3 2025 at 444,565 shares (US$17.8M). The position peaked in Q1 2026 at 1,393,027 shares, worth US$81.0M. Across 4 filings, Caligan Partners LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 889,944 shares valued at US$53.7M — a reduction of -503,083 shares quarter over quarter.. Notable position changes include a 153% increase in Q1 2026 (shares rose 4% over the following quarter), a 36% trim in Q2 2026 (shares fell 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 444.56K $17.85M New
Q4 2025 549.66K $24.64M Add
Q1 2026 1.39M $81.00M Add
Q2 2026 889.94K $53.72M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Caligan Partners LP held XENE?

Caligan Partners LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Caligan Partners LP's current position in XENE?

As of Q2 2026, Caligan Partners LP holds 889.94K shares of XENE (XENON PHARMACEUTICALS INC), valued at $53.72M, representing 3.14% of its reported portfolio and ranking #7.

Has Caligan Partners LP been buying or selling XENE?

In the latest 13F filing (Q2 2026), Caligan Partners LP reduced its position in XENE. The position peaked in Q1 2026 at 1.39M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.